Immunology Biosimilars: Webcast
MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts. 00
Ulcerative Colitis
MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira). 00
How Will Existing Contracts With AbbVie Shape Payer Strategy Towards Shifting Market Share To Biosimilars?
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts. 00
How Do Payers See The Adalimumab Biosimilar Story Playing Out In 2023?
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts. 00
Could Manufacturers Entice Payers to Make Adalimumab Coverage Decisions?
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts. 00
How Will Portfolio Contracting Impact The Number Of Adalimumab Products With Parity Access On Formulary?
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts. 00
How Will The Existence Of Medical And Pharmacy Benefits In The Market Basket For Ulcerative Colitis Affect Formulary Strategy?
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira). 00
As New Entrants Prepare To Enter The Ulcerative Colitis Market, Which Agents Will Be Disadvantaged?
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira). 00
How Does The Impending Launch Of Several New Biosimilars For Humira Impact Formulary Coverage and Market Access?
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira). 00
How Will The Complexity Of The Ulcerative Colitis Contracting Category Affect The Review Of New Entrants?
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira). 00